- Investing Ideas
- Swiss Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Swiss Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
3
1 new
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
3 companies
Sandoz Group
Market Cap: CHF 28.1b
Develops, manufactures, and markets generic and biosimilars worldwide.
New
SDZ
CHF 65.04
7D
1.6%
1Y
107.1%
Bachem Holding
Market Cap: CHF 4.8b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 63.50
7D
-4.9%
1Y
37.3%
Tecan Group
Market Cap: CHF 1.6b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 131.60
7D
-2.8%
1Y
-6.3%